Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jun 18, 2026
Accenture (ACN) Q3 Fiscal 2026 Earnings Preview: Analysts Project +6% EPS Growth on $18.8 Billion Revenue

Accenture (ACN) Q3 Fiscal 2026 Earnings Preview: Analysts Project +6% EPS Growth on $18.8 Billion Revenue

Key Takeaways

  • Accenture is scheduled to report third-quarter fiscal 2026 results before market open on June 18, 2026.
  • Analysts expect earnings per share of approximately $3.71, up about 6% from the year-ago quarter.
  • Revenue consensus stands near $18.8 billion, reflecting roughly 6% year-over-year growth.
  • Investors will focus on performance in Consulting and Managed Services segments amid ongoing AI demand.
  • Company guidance and any updates on full-year fiscal 2026 outlook will be closely monitored.
  • Historical post-earnings stock movements often hinge on beats or misses relative to these estimates.

Earnings Context and Why It Matters

Accenture’s quarterly results provide critical insight into demand for IT consulting and managed services, areas central to corporate digital transformation efforts. With a fiscal year ending August 31, the third quarter covers the period ending May 31, 2026. Recent quarters have shown steady revenue growth driven by strong bookings and AI-related projects. The upcoming report will help investors assess whether momentum in high-growth areas like artificial intelligence continues amid broader economic uncertainty. I also checked this using Tickeron’s AI Screener to see how ACN compares to peers in the industry.

Earnings Expectations

Wall Street consensus points to earnings per share of $3.71 for the third quarter of fiscal 2026, compared with $3.49 reported in the same period a year earlier. Revenue is projected at approximately $18.8 billion, versus $17.73 billion in the prior-year quarter. Segment expectations include Consulting revenue near $9.5 billion and Managed Services around $9.4 billion. Analysts also anticipate updates to full-year fiscal 2026 guidance. Accenture has historically delivered results close to or slightly above estimates, though market reaction depends on any accompanying commentary on client spending and margins. From what I see, the consistency in beating or meeting these marks has been a reliable pattern worth noting.

Market Reaction and Investor Sentiment

Sentiment ahead of the report remains cautiously optimistic, supported by Accenture’s track record of consistent growth and its positioning in high-demand technology services. Key risk factors include potential softness in discretionary consulting spending or any downward revision to guidance. Options activity and pre-earnings volatility suggest investors are positioning for a measured move, with attention centered on whether results validate ongoing AI tailwinds. One thing that stands out is how the stock has responded to similar setups in prior quarters.

Forward Outlook and Key Factors to Monitor

Following the release, investors will examine any updates to full-year fiscal 2026 revenue and earnings guidance. Commentary on new bookings, particularly in AI and cloud services, will provide clues about demand trends heading into the fourth quarter.

Segment-level performance offers additional visibility. Strength in Consulting could signal robust project pipelines, while Managed Services growth often reflects recurring revenue stability.

Broader industry conditions, including client budget allocations and competitive dynamics in digital transformation, will also shape the outlook. Margin trends and operating efficiency measures remain important watchpoints as Accenture navigates cost structures in a changing environment. I’m watching this closely for any shifts in the full-year outlook.

Using Tickeron’s AI Tools in My Research Process

In preparing for earnings seasons like this one, I often turn to Tickeron’s AI tools to supplement traditional analysis. The AI Screener stands out for its ability to quickly filter stocks and ETFs by technical patterns, fundamentals, volatility, and AI-driven signals. It allows users to scan thousands of securities with customizable filters such as industry, market capitalization, price patterns, and performance metrics, helping identify relevant trade ideas or comparable companies more efficiently than manual methods. I find this particularly useful when evaluating how a name like ACN stacks up against sector peers ahead of key reports. The platform also includes features like AI Daily Buy/Sell Signals and AI Trend Prediction Engine that can provide additional context on momentum and potential outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACN

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ACN sees its Stochastic Oscillator recovers from oversold territory

On October 01, 2026, the Stochastic Oscillator for ACN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In 44 of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 01, 2026. You may want to consider a long position or call options on ACN as a result. In 48 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.

The Moving Average Convergence Divergence (MACD) for ACN just turned positive on October 01, 2026. Looking at past instances where ACN's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.

ACN moved above its 50-day moving average on September 29, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +19.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACN advanced for three days, in 191 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

The Aroon Indicator entered an Uptrend today. In 136 of 191 cases where ACN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.

Bearish Trend Analysis

The 10-day RSI Indicator for ACN moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 24 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

ACN broke above its upper Bollinger Band on October 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.348) is normal, around the industry mean (7.462). P/E Ratio (13.935) is within average values for comparable stocks, (67.645). Projected Growth (PEG Ratio) (1.268) is also within normal values, averaging (2.284). ACN has a moderately high Dividend Yield (0.037) as compared to the industry average of (0.010). P/S Ratio (1.618) is also within normal values, averaging (141.758).

The Tickeron SMR rating for this company is 38 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ACN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are International Business Machines Corp (NYSE:IBM), Accenture PLC (NYSE:ACN), Unisys Corp (NYSE:UIS).

Industry description

The industry, whose total market cap runs into trillions, makes hardware/software that allows data to be stored, retrieved, transmitted, and manipulated on computers. With the ever-increasing relevance of data, the information technology (IT) industry has gained momentous growth over the years, and continues to thrive on innovation. Some of the behemoths in the industry are International Business Machines Corporation, Accenture, and VMware, Inc.

Market Cap

The average market capitalization across the Information Technology Services Industry is 8.39B. The market cap for tickers in the group ranges from 100 to 207.9B. IBM holds the highest valuation in this group at 207.9B. The lowest valued company is ARSC at 100.

High and low price notable news

The average weekly price growth across all stocks in the Information Technology Services Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -1%. VEEA experienced the highest price growth at 100%, while SGRX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Information Technology Services Industry was 40%. For the same stocks of the Industry, the average monthly volume growth was 43% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 64
Price Growth Rating: 60
SMR Rating: 73
Profit Risk Rating: 93
Seasonality Score: 11 (-100 ... +100)
View a ticker or compare two or three
ACN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an investment holding company with interest in providing management consulting, technology and outsourcing services

Industry InformationTechnologyServices

Industry
Information Technology Services
Address
1 Grand Canal Square
Phone
+353 16462000
Employees
779000
Web
https://www.accenture.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
Accenture (ACN) Q3 Fiscal 2026 Earnings Preview: Analysts Project +6% EPS Growth on $18.8 Billion Revenue